metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-29 THE LIVER IN AMYLOIDOSIS: AN ANALYSIS OF THE INSTITUTIONAL AMYLOIDOSIS REGI...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P-29 THE LIVER IN AMYLOIDOSIS: AN ANALYSIS OF THE INSTITUTIONAL AMYLOIDOSIS REGISTRY
Visitas
188
María Adela Aguirre1, Marcelina Carretero2, Eugenia Villanueva3, Elsa Mercedes Nucifora4, María Soledad Saez5, Erika Bárbara Brulc4, Diego Pérez De Arenaza3, Sebastián Marciano6, María Agustina Marco1, Gisela Bendelman1, Patricia Beatriz Sorroche5, María Lourdes Posadas Martínez1,5
1 Medical Clinic Service, Buenos Aires Italian Hospital, Buenos Aires, Argentina. Institute of Translational Medicine and Biomedical Engineering (IMTIB) Executing Unit of CONICET
2 Internal Medicine Research Area, Medical Clinic Department, Buenos Aires Italian Hospital, Buenos Aires, Argentina
3 Cardiology Department, Buenos Aires Italian Hospital, Buenos Aires, Argentina
4 Hematology Department, Buenos Aires Italian Hospital, Buenos Aires, Argentina
5 Institute of Translational Medicine and Biomedical Engineering (IMTIB) Executing Unit of CONICET. Non-Sponsored Research Area, Research Department, Internal Medicine Research Area, Medical Clinic Service, Buenos Aires Italian Hospital, Buenos Aires, Argentina
6 Section of Hepatology, Buenos Aires Italian Hospital, Buenos Aires, Argentina
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

The liver can be either compromised by infiltrative damage of amyloid, as it happens in AL and AA amyloidosis, or its cause, as it occurs in transthyretin TTR-related amyloidosis. In the latter, the liver synthesizes a defective variant TTR which has the capacity for cardiac, neurological, and renal damage, but the liver function is preserved. This study aimed to describe the clinical characteristics and prognosis of patients with liver involvement of amyloidosis (AL and AA)

Materials and Methods

Retrospective cohort of patients with hepatic involvement included in the Institutional Amyloidosis Registry (ClinicalTrials.gov NCT01347047) between June 2010 and January 2022. Clinical characteristics and complementary studies were analyzed, as well as their evolution.

Results

359 patients with amyloidosis were included in the registry, of whom 16 (5% (CI 2.7-7.3)) had liver involvement. The most frequent types of amyloidosis were: AL 88% (14), AA 6% (1) and non-typed 6% (1). The median age at diagnosis was 64 years (IR 63-74), male 44% (7). The median albumin value was 3.0 gr/dL (IR 2.5-3.8), alkaline phosphatase 705 IU (IR 395-114), total bilirubin mg/dL 1.1 (IR 0.5-14.8), and more than 25% had jaundice. Thirty-one percent presented a cardiac compromise. The mortality rate in the study period was 56% (CI 30%-80%). When comparing patients with amyloidosis with and without liver involvement, mortality was higher in the liver involvement group (29% vs. 56%, p 0.02).

Conclusions

​We present the first report in our region with adequate sampling that allows us to approximate the burden of this disease in relation to the liver. Hepatic infiltrative involvement has a high mortality rate in amyloidosis ​​compared to those without liver involvement.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos